Insider Trading Alert - MW, SCLN And ATHN Traded By Insiders

Yesterday, Nov. 10, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $354.40 to $12,639,826.44.

Highlighted Stocks Traded by Insiders:

Men's Wearhouse (MW) - FREE Research Report

Edwab David H, who is Director at Men's Wearhouse, bought 11,000 shares at $22.11 on Nov. 10, 2015. Following this transaction, the Director owned 29,305 shares meaning that the stake was boosted by 60.09% with the 11,000-share transaction.

The shares most recently traded at $21.82, down $0.29, or 1.33% since the insider transaction. Historical insider transactions for Men's Wearhouse go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Men's Wearhouse has been 1.7 million shares per day over the past 30 days. Men's Wearhouse has a market cap of $1.1 billion and is part of the services sector and retail industry. Shares are down 49.99% year-to-date as of the close of trading on Tuesday.

The Men's Wearhouse, Inc. operates as a specialty apparel retailer in the United States, Puerto Rico, and Canada. The company operates in two segments, Retail and Corporate Apparel. The stock currently has a dividend yield of 3.27%. Currently, there is 1 analyst who rates Men's Wearhouse a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MW - FREE

TheStreet Quant Ratings rates Men's Wearhouse as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, generally higher debt management risk and disappointing return on equity. Get the full Men's Wearhouse Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

SciClone Pharmaceuticals (SCLN) - FREE Research Report

Cheung Wilson Wai-Shun, who is CFO & Senior VP, Finance at SciClone Pharmaceuticals, sold 7,803 shares at $9.51 on Nov. 10, 2015. Following this transaction, the CFO & Senior VP, Finance owned 0 shares meaning that the stake was reduced by 100% with the 7,803-share transaction.

The shares most recently traded at $9.89, up $0.38, or 3.84% since the insider transaction. Historical insider transactions for SciClone Pharmaceuticals go as follows:

  • 4-Week # shares sold: 11,982
  • 12-Week # shares sold: 11,982
  • 24-Week # shares sold: 11,982

The average volume for SciClone Pharmaceuticals has been 385,200 shares per day over the past 30 days. SciClone Pharmaceuticals has a market cap of $401.5 million and is part of the health care sector and drugs industry. Shares are up 10.27% year-to-date as of the close of trading on Tuesday.

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the United States, and Hong Kong. The company has a P/E ratio of 20.5. Currently, there are no analysts who rate SciClone Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCLN - FREE

TheStreet Quant Ratings rates SciClone Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full SciClone Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AthenaHealth (ATHN) - FREE Research Report

Kahane Stephen N, who is EVP Client Organization at AthenaHealth, sold 5,000 shares at $159.51 on Nov. 10, 2015. Following this transaction, the EVP Client Organization owned 19,109 shares meaning that the stake was reduced by 20.74% with the 5,000-share transaction.

The shares most recently traded at $166.85, up $7.34, or 4.4% since the insider transaction. Historical insider transactions for AthenaHealth go as follows:

  • 4-Week # shares sold: 9,915
  • 12-Week # shares sold: 16,674
  • 24-Week # shares sold: 22,174

The average volume for AthenaHealth has been 482,600 shares per day over the past 30 days. AthenaHealth has a market cap of $6.4 billion and is part of the technology sector and computer software & services industry. Shares are up 14.21% year-to-date as of the close of trading on Tuesday.

athenahealth, Inc., together with its subsidiaries, operates as a business services company that provides ongoing billing, clinical-related, and other related services to medical group practices and health systems in the United States. The company has a P/E ratio of 423.3. Currently, there are 11 analysts who rate AthenaHealth a buy, 2 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATHN - FREE

TheStreet Quant Ratings rates AthenaHealth as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including premium valuation and weak operating cash flow. Get the full AthenaHealth Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Your Need to Know - Forward Look

Your Need to Know - Forward Look

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading

How E-Mini S&P 500 Revolutionized Equity, Electronic Trading